Report Overview

The EU Hepatitis B infectious market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Hepatitis B virus or HBV can cause serious infection which occurs in the body parts, affecting liver and causes liver disease such as cirrhosis or liver cancer. These infection cannot be determined at an early stage but are visible after certain weeks only. It is a disease which can occur even from birth, mainly caused due to blood transfusions through healthcare settings, dialysis and sharing razors. Hepatitis B vaccine comprises of hepatitis B surface antigen (HBsAg) along with viral envelope proteins. It is also formed using yeast cells. The medication course involves two or three injections which are given at a time interval of two to three months. Immune system memory also helps in providing resistance against the virus



Market Drivers

Increasing awareness of the disease and treatment expected to facilitate future needs is the major factor which is expected to drive this market. The development of drugs and vaccines in treating hepatitis B virus increases the growth of this market. The market will grow due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population